Obesity Drugmaker Novo Nordisk Raises Outlook, Q1 Profit Beats Forecast

Reuters05-02

LONDON, May 2 (Reuters) - Novo Nordisk raised its 2024 outlook on Thursday as it posted first-quarter operating profit above analyst forecasts.

Novo Nordisk shares slipped 2% in overnight trading.

The raised outlook and strong results underscore Wegovy's success and Novo's lead in the fast-growing obesity drug market, even as the company faces fierce competition from U.S. rival Eli Lilly.

Novo said it now expects sales growth this year of between 19% and 27% in local currencies, compared to the previously guided range for 18% to 26% growth.

Operating profit growth this year is now seen at between 22% and 30% in local currencies, slightly up from its previous forecast of 21% to 29%.

Novo reported first-quarter earnings before interest and taxation (EBIT) of 31.8 billion Danish crowns, above the 29 billion forecast by analysts in a LSEG poll this week.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment